Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
- DOI
- 10.1182/blood-2004-09-3413
- Published
- 2005 Feb 15
- Container
- Blood
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/blood-2004-09-3413,
title = {Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.},
author = {George P and Bali P and Annavarapu S and Scuto A and Fiskus W and Guo F and Sigua C and Sondarva G and Moscinski L and Atadja P and Bhalla K},
year = {2005},
journal = {Blood},
doi = {10.1182/blood-2004-09-3413},
url = {https://doi.org/10.1182/blood-2004-09-3413}
}RIS
TY - JOUR TI - Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. AU - George P AU - Bali P AU - Annavarapu S AU - Scuto A AU - Fiskus W AU - Guo F AU - Sigua C AU - Sondarva G AU - Moscinski L AU - Atadja P AU - Bhalla K PY - 2005 JO - Blood DO - 10.1182/blood-2004-09-3413 UR - https://doi.org/10.1182/blood-2004-09-3413 ER -
APA
P, G., P, B., S, A., A, S., W, F., F, G., C, S., G, S., L, M., P, A., & K, B. (2005). Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.. Blood. https://doi.org/10.1182/blood-2004-09-3413
Source records
- pubmed · retrieved 2026-09-26T01:10:19.367Z